Growth Inhibitory and Pro-Apoptotic Effects of Hirsuteine in Chronic Myeloid Leukemia Cells through Targeting Sphingosine Kinase 1 |
Gao, Shan
(Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University)
Guo, Tingting (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Luo, Shuyu (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Zhang, Yan (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Ren, Zehao (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Lang, Xiaona (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Hu, Gaoyong (State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine) Zuo, Duo (Department of Clinical Laboratory, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University) Jia, Wenqing (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Kong, Dexin (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) Yu, Haiyang (State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine) Qiu, Yuling (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University) |
1 | Pitman, M. R. and Pitson, S. M. (2010) Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr. Cancer Drug Targets 10, 354-367. DOI |
2 | Pitson, S. M., Moretti, P. A. B., Zebol, J. R., Lynn, H. E., Xia, P., Vadas, M. A. and Wattenberg, B. W. (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22, 5491-5500. DOI |
3 | Ren, S. Y., Xin, C. Y., Pfeilschifter, J. and Huwiler, A. (2010) A novel mode of action of the putative sphingosine kinase inhibitor 2-(phydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell. Physiol. Biochem. 26, 97-104. DOI |
4 | Sukocheva, O. A., Furuya, H., Ng, M. L., Friedemann, M., Menschikowski, M., Tarasov, V. V., Chubarev, V. N., Klochkov, S. G., Neganova, M. E., Mangoni, A. A., Aliev, G. and Bishayee, A. (2020) Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target. Pharmacol. Ther. 207, 107464. DOI |
5 | Huang, B. Y., Zeng, Y., Li, Y. J., Huang, X. J., Hu, N., Yao, N., Chen, M. F., Yang, Z. G., Chen, Z. S., Zhang, D. M. and Zeng, C. Q. (2017) Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. Int. J. Oncol. 51, 257-268. DOI |
6 | Blaho, V. A. and Hla, T. (2014) An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 55, 1596-1608. DOI |
7 | Codini, M., Garcia-Gil, M. and Albi, E. (2021) Cholesterol and sphingolipid enriched lipid rafts as therapeutic targets in cancer. Int. J. Mol. Sci. 22, 726. DOI |
8 | Cortes, J. and Lang, F. B. (2021) Third-line therapy for chronic myeloid leukemia: current status and future directions. J. Hematol. Oncol. 14, 44. DOI |
9 | Ding, T. D., Zhi, Y., Xie, W. L., Yao, Q. Q. and Liu, B. (2021) Rational design of SphK inhibitors using crystal structures aided by computer. Eur. J. Med. Chem. 213, 113164. DOI |
10 | Hannun, Y. A. and Obeid, L. M. (2018) Author correction: sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 19, 673. DOI |
11 | Kushida, H., Matsumoto, T. and Ikarashi, Y. (2021) Properties, pharmacology, and pharmacokinetics of active indole and oxindole alkaloids in uncaria hook. Front. Pharmacol. 12, 688670. DOI |
12 | Li, Q. F., Huang, W. R., Duan, H. F., Wang, H., Wu, C. T. and Wang, L. S. (2007) Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 26, 7904-7908. DOI |
13 | Liu, H. W., Chen, Q., Lu, D., Pang, X., Yin, S. S., Wang, K. L., Wang, R., Yang, S. S., Zhang, Y., Qiu, Y. L., Wang, T. and Yu, H. Y. (2020) HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt. FASEB J. 34, 12255-12268. DOI |
14 | Jairajpuri, D. S., Mohammad, T., Adhikari, K., Gupta, P., Hasan, G. M., Alajmi, M. F., Rehman, M. T., Hussain, A. and Hassan, M. I. (2020) Identification of sphingosine kinase-1 inhibitors from bioactive natural products targeting cancer therapy. ACS Omega 5, 14720-14729. DOI |
15 | Amir, M. and Javed, S. (2021) A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs. Front. Genet. 12, 742802. DOI |
16 | Companioni, O., Mir, C., Garcia-Mayea, Y. and LLeonart, M. E. (2021) Targeting sphingolipids for cancer therapy. Front. Oncol. 11, 745092. DOI |
17 | Green, C. D., Maceyka, M., Cowart, L. A. and Spiegel, S. (2021) Sphingolipids in metabolic disease: the good, the bad, and the unknown. Cell Metab. 33, 1293-1306. DOI |
18 | Lion, T. (2011) SP 108 resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Eur. J. Cancer 47, S3. DOI |
19 | Mohd Sairazi, N. S. and Sirajudeen, K. N. S. (2020) Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases. Evid. Based Complement. Alternat. Med. 2020, 6565396. |
20 | Patmanathan, S. N., Wang, W., Yap, L. F., Herr, D. R. and Paterson, I. C. (2017) Mechanisms of sphingosine 1-phosphate receptor signalling in cancer. Cell. Signal. 34, 66-75. DOI |
21 | Zheng, X. J., Li, W., Ren, L. W., Liu, J. Y., Pang, X. C., Chen, X. P., Kang, D., Wang, J. H. and Du, G. H. (2019) The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: potential target for anticancer therapy. Pharmacol. Ther. 195, 85-99. DOI |
22 | Qi, W., Yue, S. J., Sun, J. H., Simpkins, J. W., Zhang, L. and Yuan, D. (2014) Alkaloids from the hook-bearing branch of Uncaria rhynchophylla and their neuroprotective effects against glutamate-induced HT22 cell death. J. Asian Nat. Prod. Res. 16, 876-883. DOI |
23 | Velazquez, F. N., Hernandez-Corbacho, M., Trayssac, M., Stith, J. L., Bonica, J., Jean, B., Pulkoski-Gross, M. J., Carroll, B. L., Salama, M. F., Hannun, Y. A. and Snider, A. J. (2021) Bioactive sphingolipids: advancements and contributions from the laboratory of Dr. Lina M. Obeid. Cell. Signal. 79, 109875. DOI |
24 | Yin, S. S., Yang, S. S., Luo, Y. M., Lu, J., Hu, G. Y., Wang, K. L., Shao, Y. Y., Zhou, S. Y., Koo, S., Qiu, Y. L., Wang, T. and Yu, H. Y. (2021) Cyclin-dependent kinase 1 as a potential target for lycorine against hepatocellular carcinoma. Biochem. Pharmacol. 193, 114806. DOI |
25 | Lupino, L., Perry, T., Margielewska, S., Hollows, R., Ibrahim, M., Care, M., Allegood, J., Tooze, R., Sabbadini, R., Reynolds, G., Bicknell, R., Rudzki, Z., Lin, Hock. Y., Zanetto, U., Wei, W., Simmons, W., Spiegel, S., Woodman, C. B. J., Rowe, M., Vrzalikova, K. and Murray, P. G. (2019) Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. Leukemia 33, 2884-2897. DOI |
26 | Wilson, B. A. P., Thornburg, C. C., Henrich, C. J., Grkovic, T. and O'Keefe, B. R. (2020) Creating and screening natural product libraries. Nat. Prod. Rep. 37, 893-918. DOI |
27 | Yin, S. S., Qiu, Y. L., Jin, C. Y., Wang, R., Wu, S., Liu, H. W., Koo, S., Han, L. F., Zhang, Y., Gao, X. M., Pang, X., Wang, T. and Yu, H. Y. (2019) 7-Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma. Int. J. Cancer 145, 3334-3346. DOI |
28 | Yu, H. Y., Yin, S. S., Zhou, S. Y., Shao, Y. Y., Sun, J. C., Pang, X., Han, L. F., Zhang, Y., Gao, X. M., Jin, C. Y., Qiu, Y. L. and Wang, T. (2018) Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers. Cell Death Dis. 9, 702 DOI |
29 | Zhang, L., Chen, T., Dou, Y. H., Zhang, S. L., Liu, H. Y., Khishignyam, T., Li, X. F., Zuo, D., Zhang, Z., Jin, M. H., Wang, R., Qiu, Y. L., Zhong, Y. X. and Kong, D. X. (2019) Atorvastatin exerts antileukemia activity via inhibiting mevalonate-YAP axis in K562 and HL60 cells. Front. Oncol. 9, 1032. DOI |
30 | Zhou, Q. X., Chen, Y. L., Chen, X., Zhao, W. N., Zhong, Y. X., Wang, R., Jin, M. H., Qiu, Y. L. and Kong, D. X. (2016) In vitro antileukemia activity of ZSTK474 on K562 and multidrug resistant K562/A02 cells. Int. J. Biol. Sci. 12, 631-638. DOI |
31 | Mojtahedi, H., Yazdanpanah, N. and Rezaei, N. (2021) Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res. Ther. 12, 603. DOI |
32 | Osman, A. E. G. and Deininger, M. W. (2021) Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 49, 100825. DOI |